# IgIV Plus Prednisone vs High-dose Dexamethasone for ITP

> **NCT04968899** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 272 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Neofordex®
- **DRUG:** Intravenous immunoglobulins

## Key facts

- **NCT ID:** NCT04968899
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-07
- **Primary completion:** 2025-04-09
- **Final completion:** 2026-10-09
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04968899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04968899, "IgIV Plus Prednisone vs High-dose Dexamethasone for ITP". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04968899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*